Vanderbilt Institute for Global Health (VIGH) has received a new research training grant and a renewal for an existing training program from the Fogarty International Center (FIC) of the National Institutes of Health (NIH) to build HIV-focused research capacity with key partners in Nigeria and Mozambique.

Out of concern for fetal safety, pregnant people have typically been excluded from drug trials. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive.

The National Institutes of Health (NIH) has renewed its support of the Tennessee Center for AIDS Research (CFAR), a four-way partnership between Vanderbilt University Medical Center, Meharry Medical College, the Tennessee Department of Health and Nashville CARES.

According to the U.S. Centers for Disease Control and Prevention, fewer than 1% of the population is truly allergic to penicillin. The rest were never allergic to begin with or have outgrown their allergy — an estimated 80% of people with penicillin allergy lose their sensitivity to the drug within 10 years.

Vanderbilt infectious diseases specialist Thomas Talbot, MD, MPH, answers questions about the current novel coronavirus outbreak in China.

The Division of Infectious Diseases at Vanderbilt University Medical Center is seeking applicants for its new Transplant and Immunocompromised Host Infectious Diseases Fellowship Program.

The Division of Infectious Diseases is seeking applicants for its new Transplant Infectious Diseases/Immunocompromised Host (TID/ICH) Fellowship Program.